• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Introducing The VEAZY: STORZ & BICKEL's Most Compact and Accessible Vaporizer

    9/9/25 12:00:00 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $CGC alert in real time by email

    Sleek portability. Precision engineering. Premium performance. Four exciting new colors

    STORZ & BICKEL GmbH ("STORZ & BICKEL" or the "Company"), a world-leading manufacturer of high-end, medically certified cannabis vaporizers and a subsidiary of Canopy Growth Corporation (TSX:WEED) (NASDAQ:CGC), today unveiled the VEAZY— an accessible new addition to its premium portfolio, extending the Company's precision engineering to a broader audience.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250909162411/en/

    Introducing The VEAZY: STORZ & BICKEL's Most Compact and Accessible Vaporizer

    Introducing The VEAZY: STORZ & BICKEL's Most Compact and Accessible Vaporizer

    The VEAZY delivers an uncompromising solution, designed to be as approachable as it is easy to use. The VEAZY is the first vaporizer from STORZ & BICKEL to be available in multiple colors that blend style with function—Charming Pink, Inspiring Orange, Dynamic Blue and Alluring Black.

    VEAZY Key Features:

    • Compact Precision – At just 0.3lbs, it's the smallest device in the portfolio, built for portability without compromise.
    • Customizable Style – Four distinct colorways make it the brands most vibrant and personal device yet.
    • Premium Vaporizer Quality – A patented mini heater, combining conduction and convection, delivers consistently dense, flavorful vapor.
    • Effortless Usability – With one-button control, three pre-set temperatures, and rapid ~40-second heat-up, VEAZY is simple for beginners and reliable for experts.
    • Accessible Value – With a $249 USD price point, the VEAZY makes STORZ & BICKEL's world-class engineering more attainable than ever.
    • Worldwide Availability – The VEAZY will be available for purchase online and in-store at select retailers in upwards of 100 countries worldwide.
    • Bluetooth Compatible – The VEAZY connects via Bluetooth to the STORZ & BICKEL web app, allowing users to fine-tune settings and personalize sessions directly from their phone or laptop.
    • Fast Charging – A USB-C charging system powers the device to 80% in just 40 minutes.

    "Consumers have been asking for a vaporizer that combines accessibility with style," said Jürgen Bickel, Managing Director & Co-Founder, STORZ & BICKEL. "With the VEAZY, we're expanding the STORZ & BICKEL experience to a new audience while staying true to the superior standards that have defined us for over 25 years."

    The VEAZY is available online at storz-bickel.com and at select licensed retailers worldwide.

    To stay up-to-date on the latest product news, follow @storz.bickel on Instagram.

    About STORZ & BICKEL GmbH

    STORZ & BICKEL GmbH is the global leader in the manufacture of high-end and medically certified cannabis vaporizers. With a commitment to quality, innovation, and compliance, the company has consistently delivered exceptional products that meet the highest industry standards. Based in Tuttlingen, Germany, STORZ & BICKEL continues to drive the advancement of vaporization technology, providing a safe and efficient means of consuming cannabis for medical purposes. For more information, visit www.storz-bickel.com

    About Canopy Growth

    Canopy Growth is a world-leading cannabis company dedicated to unleashing the power of cannabis to improve lives. Through an unwavering commitment to consumers, Canopy Growth delivers innovative products from owned and licensed brands including Tweed, 7ACRES, DOJA, Deep Space, and Claybourne, as well as category defining vaporization devices by Storz & Bickel. In addition, Canopy Growth serves medical cannabis patients globally with principal operations in Canada, Europe and Australia.

    Canopy Growth has also established a comprehensive ecosystem to realize the opportunities presented by the U.S. THC market through an unconsolidated, non-controlling interest in Canopy USA, LLC ("Canopy USA"). Canopy USA's portfolio includes ownership of Acreage Holdings, Inc., a vertically integrated multi‑state cannabis operator with operations throughout the U.S. Northeast and Midwest, as well as ownership of Wana Wellness, LLC, The Cima Group, LLC, and Mountain High Products, LLC, a leading North American edibles brand, and majority ownership of Lemurian, Inc., a California-based producer of high-quality cannabis extracts and clean vape technology.

    At Canopy Growth, we're shaping a future where cannabis is embraced for its potential to enhance well-being and improve lives. With high-quality products, a commitment to responsible use, and a focus on enhancing the communities where we live and work, we're paving the way for a better understanding of all that cannabis can offer. For more information, visit www.canopygrowth.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250909162411/en/

    Media Contacts:



    Vatra Krasniqi, STORZ & BICKEL

    Head of Marketing and Communications

    [email protected]



    Vanessa Jenkins, Canopy Growth

    Communications

    [email protected]

    Get the next $CGC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CGC

    DatePrice TargetRatingAnalyst
    11/10/2025Sell → Hold
    The Benchmark Company
    4/4/2023Underperform → Mkt Perform
    Bernstein
    11/2/2022$1.50Underperform
    Bernstein
    10/26/2022Sell → Hold
    Canaccord Genuity
    6/8/2022Market Perform → Underperform
    BMO Capital Markets
    3/22/2022Equal Weight → Underweight
    Barclays
    3/1/2022$14.00 → $9.00Equal-Weight
    Barclays
    2/18/2022$9.60 → $11.00Neutral
    Cantor Fitzgerald
    More analyst ratings

    $CGC
    SEC Filings

    View All

    SEC Form S-3 filed by Canopy Growth Corporation

    S-3 - Canopy Growth Corp (0001737927) (Filer)

    2/6/26 4:15:52 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Canopy Growth Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Canopy Growth Corp (0001737927) (Filer)

    2/6/26 7:05:59 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 10-Q filed by Canopy Growth Corporation

    10-Q - Canopy Growth Corp (0001737927) (Filer)

    2/6/26 6:45:57 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    $CGC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Mongeau Luc sold $9,951 worth of shares (9,376 units at $1.06), decreasing direct ownership by 1% to 802,992 units (SEC Form 4)

    4 - Canopy Growth Corp (0001737927) (Issuer)

    2/12/26 7:53:43 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Yanofsky Theresa sold $11,790 worth of shares (10,434 units at $1.13), decreasing direct ownership by 14% to 63,518 units (SEC Form 4)

    4 - Canopy Growth Corp (0001737927) (Issuer)

    1/2/26 4:38:18 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Lazzarato David Angelo sold $17,758 worth of shares (15,715 units at $1.13), decreasing direct ownership by 15% to 87,672 units (SEC Form 4)

    4 - Canopy Growth Corp (0001737927) (Issuer)

    1/2/26 4:37:09 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    $CGC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Canopy Growth to Report Third Quarter Fiscal 2026 Financial Results on February 6, 2026

    Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED, NASDAQ:CGC) will release its financial results for the third quarter fiscal year 2026 ended December 31, 2025 before financial markets open on February 6, 2026. Following the release of its third quarter fiscal year 2026 financial results, Canopy Growth will host an audio webcast with Luc Mongeau, CEO and Tom Stewart, CFO on February 6, 2026 at 10 AM Eastern Time (ET). Webcast Information A live audio webcast will be available at: https://onlinexperiences.com/Launch/QReg/ShowUUID=45C34153-5530-4D6A-A742-BC34AD2534FA Replay Information A replay will be accessible by webcast until 11:59 PM ET on May 7, 2026 at:

    1/23/26 7:00:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    2026 Asset Growth: Why Federal Compliance Is the New Metric

    VANCOUVER, British Columbia, Jan. 19, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – Consumer healthcare markets hit a massive $362 billion entering 2026, but smart money is shifting toward regulatory certainty rather than just market size[1]. Modern health organizations are using aggressive buyouts as a primary 2026 strategy to secure high-tech efficiency while navigating intense federal scrutiny and capital limits[2]. In this high-stakes environment, companies with a clear and proven path through federal guidelines are capturing the most attention, including Doseology Sciences Inc. (CSE:MOOD) (OTCPK:DOSEF) (FSE: VU70), Canopy Growth (NASDAQ:CGC) (TSX:WEED), Definium Therap

    1/19/26 12:20:49 PM ET
    $CGC
    $DFTX
    $KDP
    Medicinal Chemicals and Botanical Products
    Health Care
    Beverages (Production/Distribution)
    Consumer Staples

    Canopy Growth Announces Strategic Recapitalization Transactions Significantly Strengthening Balance Sheet to Support Growth Strategy

    This news release constitutes a "designated news release" for the purposes of Canopy Growth's prospectus supplement dated August 29, 2025 to its short form base shelf prospectus dated June 5, 2024 Refinances Term Loan due 2027 and Exchanges Convertible Debentures due 2029, Extending Maturities of All Outstanding Indebtedness to Earliest January 2031 While Enhancing Liquidity Profile Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC), a world-leading cannabis company dedicated to unleashing the power of cannabis to improve lives, announced today that the Company has entered into a series of transactions to recapitalize its balance sheet and extend the ma

    1/8/26 7:00:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    $CGC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Canopy Growth upgraded by The Benchmark Company

    The Benchmark Company upgraded Canopy Growth from Sell to Hold

    11/10/25 8:33:16 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Canopy Growth upgraded by Bernstein

    Bernstein upgraded Canopy Growth from Underperform to Mkt Perform

    4/4/23 9:09:41 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Bernstein initiated coverage on Canopy Growth with a new price target

    Bernstein initiated coverage of Canopy Growth with a rating of Underperform and set a new price target of $1.50

    11/2/22 6:11:10 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    $CGC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Mongeau Luc bought $49,994 worth of shares (27,469 units at $1.82), increasing direct ownership by 3% to 812,368 units (SEC Form 4)

    4 - Canopy Growth Corp (0001737927) (Issuer)

    9/23/25 4:15:11 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    $CGC
    Leadership Updates

    Live Leadership Updates

    View All

    Canopy Growth to Acquire MTL Cannabis; Transaction Expected to Create Canada's Leading Medical Cannabis Business and Enhance Capacity to Serve Growing International Demand

    This news release constitutes a "designated news release" for the purposes of Canopy Growth's prospectus supplement dated August 29, 2025 to its short form base shelf prospectus dated June 5, 2024 All financial amounts in this press release are expressed in Canadian dollars. Highly accretive business combination expected to generate significant run-rate synergies of approximately $10 million within 18 months Strengthens Canopy Growth's presence in Québec with an opportunity to expand national distribution of MTL's high-quality, budtender-recommended product portfolio2 MTL's core management team is expected to join Canopy Growth to drive cultivation excellence and enhance the Company's p

    12/15/25 7:00:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Canopy Growth Announces Results of Annual General and Special Meeting of Shareholders

    Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC), a world-leading cannabis company dedicated to unleashing the power of cannabis to improve lives, is pleased to announce today the voting results from its Annual General and Special Meeting of Shareholders convened on September 26, 2025 and adjourned to, and reconvened on, October 10, 2025 (the "Meeting"). All of the matters put forward before the Company's shareholders for consideration and approval, as set out in the Company's definitive proxy statement dated August 7, 2025 (the "Proxy Statement"), were approved by the requisite number of votes cast at the Meeting, as further detailed below. Each of t

    10/14/25 7:00:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Canopy Growth Appoints Tom Stewart as Chief Financial Officer

    Appointment finalizes CFO transition and reinforces Canopy Growth's focus on operational discipline, financial stability, and long-term value creation Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC), a world-leading cannabis company dedicated to unleashing the power of cannabis to improve lives, today announced that Tom Stewart has been appointed Chief Financial Officer, effective immediately. Mr. Stewart's appointment supports the continued execution of Canopy Growth's fiscal year 2026 strategy, which is marked by structural efficiency, operational and commercial focus, and disciplined capital allocation and cost management. With significant progres

    9/17/25 7:00:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    $CGC
    Financials

    Live finance-specific insights

    View All

    Canopy Growth to Report Third Quarter Fiscal 2026 Financial Results on February 6, 2026

    Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED, NASDAQ:CGC) will release its financial results for the third quarter fiscal year 2026 ended December 31, 2025 before financial markets open on February 6, 2026. Following the release of its third quarter fiscal year 2026 financial results, Canopy Growth will host an audio webcast with Luc Mongeau, CEO and Tom Stewart, CFO on February 6, 2026 at 10 AM Eastern Time (ET). Webcast Information A live audio webcast will be available at: https://onlinexperiences.com/Launch/QReg/ShowUUID=45C34153-5530-4D6A-A742-BC34AD2534FA Replay Information A replay will be accessible by webcast until 11:59 PM ET on May 7, 2026 at:

    1/23/26 7:00:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Canopy Growth Reports Second Quarter Fiscal 2026 Financial Results; Company Continues to Strengthen Financial Performance with Improving Adjusted EBITDA, Disciplined Cost Management, and a Stronger Balance Sheet

    Canada adult-use revenue up 30% in Q2 FY2026 and 37% year-to-date, reflecting the benefits of our focused commercial strategy and more disciplined execution Canada medical revenue up 17% in Q2 FY2026 and 15% year-to-date, marking another standout quarter for growth $298MM cash and cash equivalents, which exceeds debt balances by $70MM at September 30, 2025; as a result, conditions that previously raised substantial doubt concerning the Company's ability to continue as a going concern have been resolved Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC) today announced its financial results for the second quarter ended September 30, 2025 ("Q2 FY2026"). Al

    11/7/25 7:00:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Canopy Growth to Report Second Quarter Fiscal 2026 Financial Results on November 7, 2025

    Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED, NASDAQ:CGC) will release its financial results for the second quarter fiscal year 2026 ended September 30, 2025 before financial markets open on November 7, 2025. Following the release of its second quarter fiscal year 2026 financial results, Canopy Growth will host an audio webcast with Luc Mongeau, CEO and Tom Stewart, CFO on November 7, 2025 at 10 AM Eastern Time (ET). Webcast Information A live audio webcast will be available at: https://onlinexperiences.com/Launch/QReg/ShowUUID=EEDC9A65-53FA-40BD-9644-D3ABDCF91E72 Replay Information A replay will be accessible by webcast until 11:59 PM ET on February 5, 2026

    10/24/25 7:00:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    $CGC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Canopy Growth Corporation (Amendment)

    SC 13D/A - Canopy Growth Corp (0001737927) (Subject)

    4/19/24 5:00:49 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13D/A filed by Canopy Growth Corporation (Amendment)

    SC 13D/A - Canopy Growth Corp (0001737927) (Subject)

    11/3/23 4:30:53 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13D/A filed by Canopy Growth Corporation (Amendment)

    SC 13D/A - Canopy Growth Corp (0001737927) (Subject)

    7/20/23 4:35:52 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care